Skip to main content
Top
Published in: Pediatric Cardiology 5/2012

01-06-2012 | Original Article

Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Authors: Song I Yang, Wook Jin Chung, Sung Hwan Jung, Deok Young Choi

Published in: Pediatric Cardiology | Issue 5/2012

Login to get access

Abstract

Identification of the pathophysiology associated with Eisenmenger syndrome has led to the evaluation of targeted therapies. Iloprost is one such targeted therapy used for patients with Eisenmenger syndrome. This study aimed to assess the efficacy and safety of iloprost used for patients with Eisenmenger syndrome. In this study, 12 patients with Eisenmenger syndrome (mean age, 33.2 ± 12.1 years; 75% female) started receiving iloprost 10 μg/dose administered six times a day. Of the 12 patients, 9 were classified as New York Heart Association (NYHA) functional class 3, and three were categorized as functional class 4. Changes in 6-min walk distance, NYHA functional class, oxygen saturation at resting, and results after the 6-min walk test were checked, as well as changes in right ventricle diameter and pulmonary arterial pressure shown by echocardiography. The distance during a 6-min walk increased from 255.8 ± 120.4 to 349.4 ± 134.7 m (p = 0.013), and 10 patients improved their NYHA functional class by one grade (p = 0.007). The mean resting oxygen saturation (SpO2) increased from 80.6 ± 14.2 to 84.9 ± 13.0% (p = 0.040), and after the 6-min walk test, it increased from 63.8 ± 22.9 to 68.8 ± 21.5% (p = 0.007). The mean right ventricle diameter during the diastolic phase changed from 53.7 ± 4.8 to 51.4 ± 3.9 mm (p = 0.068), and the mean pulmonary arterial pressure changed from 62.8 ± 13.7 to 58.9 ± 11.7 mmHg (p = 0.059). Neither death nor critical adverse effects occurred for any patients. Mild headache and dyspnea were common reports during the iloprost treatments. No patients stopped the therapy due to these adverse effects. Iloprost is well tolerated and appears to be beneficial in the management of patients with Eisenmenger syndrome.
Literature
1.
go back to reference Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334:296–302PubMedCrossRef Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334:296–302PubMedCrossRef
2.
go back to reference Beghetti M, Galie N (2009) Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53:733–740PubMedCrossRef Beghetti M, Galie N (2009) Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53:733–740PubMedCrossRef
3.
go back to reference Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S (1998) Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 19:1845–1855PubMedCrossRef Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S (1998) Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 19:1845–1855PubMedCrossRef
4.
go back to reference Eisenmenger V (1897) Die angeborenen Defecte der Kammerscheidewand des Herzens. Z Klin Med 32:1–28 Eisenmenger V (1897) Die angeborenen Defecte der Kammerscheidewand des Herzens. Z Klin Med 32:1–28
5.
go back to reference Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157PubMedCrossRef Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157PubMedCrossRef
6.
go back to reference Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Gremminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:158–164PubMedCrossRef Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Gremminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:158–164PubMedCrossRef
7.
go back to reference Goldsmith DR, Wagstaff AJ (2004) Inhaled iloprost: in primary pulmonary hypertension. Drugs 64:763–773PubMedCrossRef Goldsmith DR, Wagstaff AJ (2004) Inhaled iloprost: in primary pulmonary hypertension. Drugs 64:763–773PubMedCrossRef
8.
go back to reference Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Resp J 4:691–694CrossRef Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Resp J 4:691–694CrossRef
9.
go back to reference Hopkins WE, Ochoa LL, Richardson GW, Trulock EP (1996) Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15:100–105PubMed Hopkins WE, Ochoa LL, Richardson GW, Trulock EP (1996) Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15:100–105PubMed
10.
go back to reference McLoughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Resp Crit Care Med 174:1257–1263CrossRef McLoughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Resp Crit Care Med 174:1257–1263CrossRef
11.
go back to reference Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM (2008) Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J 35:256–261PubMed Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM (2008) Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J 35:256–261PubMed
12.
go back to reference Oh JK, Seward JB, Tajik AJ (2006) The echo manual, 3rd edn. Lippincott Willams & Wilkins, Philadelphia, p 147 Oh JK, Seward JB, Tajik AJ (2006) The echo manual, 3rd edn. Lippincott Willams & Wilkins, Philadelphia, p 147
13.
go back to reference Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322e9CrossRef Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322e9CrossRef
14.
go back to reference Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102:139–153PubMedCrossRef Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102:139–153PubMedCrossRef
15.
go back to reference Oya H, Nagaya N, Uematsu M, Satoh T, Sakamaki F, Kyotani S, Sato N, Nakanishi N, Miyatake K (2002) Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 143:739–744PubMedCrossRef Oya H, Nagaya N, Uematsu M, Satoh T, Sakamaki F, Kyotani S, Sato N, Nakanishi N, Miyatake K (2002) Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 143:739–744PubMedCrossRef
16.
go back to reference Pietra GG, Capron F, Stewart S, Leone O, Humber DM, Reid L, Grimminger F, Robbins I, Tuder RM (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(1):S25–S32CrossRef Pietra GG, Capron F, Stewart S, Leone O, Humber DM, Reid L, Grimminger F, Robbins I, Tuder RM (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(1):S25–S32CrossRef
17.
go back to reference Reichenberger F, Mainwood A, Coughty N, Fineberg A, Morrell NW, Pepke-Zaba J (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med 101:217–222PubMedCrossRef Reichenberger F, Mainwood A, Coughty N, Fineberg A, Morrell NW, Pepke-Zaba J (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med 101:217–222PubMedCrossRef
18.
go back to reference Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMedCrossRef Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMedCrossRef
19.
go back to reference Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W (2005) Inhaled iloprost reversed vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172:336–358CrossRef Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W (2005) Inhaled iloprost reversed vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172:336–358CrossRef
20.
go back to reference Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804PubMed Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804PubMed
21.
go back to reference Vongpatanasin W, Brickner ME, Hillis LD, Lange RA (1998) The Eisenmenger syndrome in adults. Ann Intern Med 128:745–755PubMed Vongpatanasin W, Brickner ME, Hillis LD, Lange RA (1998) The Eisenmenger syndrome in adults. Ann Intern Med 128:745–755PubMed
22.
go back to reference Wagenvoort CA, Wagenvoort N (1974) Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 11:123–130PubMed Wagenvoort CA, Wagenvoort N (1974) Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 11:123–130PubMed
23.
go back to reference Wilkens H, Guth A, Koenig J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht G (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222PubMedCrossRef Wilkens H, Guth A, Koenig J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht G (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222PubMedCrossRef
24.
go back to reference Wood P (1958) The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 2:701–709PubMedCrossRef Wood P (1958) The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 2:701–709PubMedCrossRef
Metadata
Title
Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Authors
Song I Yang
Wook Jin Chung
Sung Hwan Jung
Deok Young Choi
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Pediatric Cardiology / Issue 5/2012
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-012-0204-0

Other articles of this Issue 5/2012

Pediatric Cardiology 5/2012 Go to the issue